跳至主要内容
临床试验/NCT01849952
NCT01849952终止不适用

Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas

Dartmouth-Hitchcock Medical Center4 个研究点 分布在 1 个国家目标入组 94 人开始时间: 2013年10月9日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
94
试验地点
4
主要终点
Overall Survival

研究概览

简要总结

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 18 years of age
  • Brain tumor(s) to be resected for clinical reasons.
  • Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV.
  • Adequate tissue available for processing as determined by Pathology.
  • Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment.
  • Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.

结局指标

主要结局

Overall Survival

时间窗: 24 months

Patients will be followed for survival every 12 weeks +/- 1 week.

次要结局

  • Progression-Free Survival(24 Months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验